UK Point of Care Diagnostics Market (2024-2029)
The UK Point of Care Diagnostics Market was valued at $257.9 Million in 2024 and projected to reach to $434.7 Million by 2029, representing a compound annual growth rate of 11.0%. The UK Point of Care Diagnostics Market is positioned for sustained expansion through 2029, driven by NHS modernization initiatives, increased funding for diagnostic capabilities, and growing patient demand for rapid testing solutions.
UK Point of Care Diagnostics Market Trends and Insights
- The UK market is expanding at an 11.0% compound annual growth rate, outpacing global trends and reflecting strong demand for rapid diagnostic solutions across healthcare settings.
- This acceleration in the UK is driven by increased adoption of point-of-care testing in primary care, urgent care centres, and community health settings, where speed and accessibility are critical. The UK's healthcare infrastructure and emphasis on early disease detection are key catalysts for market expansion through 2029.
- The UK market benefits from NHS modernisation initiatives and growing patient preference for convenient, non-invasive diagnostic options.
- Investment in digital health integration and point-of-care device innovation continues to position the UK as a significant market within Europe, with particular strength in infectious disease testing, cardiac markers, and glucose monitoring segments..
Key Market Statistics
- CAGR (2024-2029) 11.0% CAGR
- Market Size, 2024 ~USD 257.9 Million
- Forecast, 2029 ~USD 434.7 Million
- Country UK
UK Point of Care Diagnostics Market Overview
Market Valuation Growth :
The UK Point of Care Diagnostics Market is valued at £257.9 million in 2024, with projections reaching £434.7 million by 2029, representing a robust 11% CAGR that significantly outpaces the global average of 8.5%.
Accelerated UK Adoption :
The UK market is experiencing faster growth than global trends, driven by increased NHS adoption of rapid diagnostic solutions, enhanced point-of-care testing infrastructure, and growing demand for decentralized diagnostics across primary and secondary care settings.
Healthcare System Integration :
UK healthcare providers are rapidly integrating POC diagnostics into clinical workflows, supported by government initiatives promoting faster patient diagnosis, reduced hospital burden, and improved access to testing in community and primary care environments.
Technology & Innovation Focus :
The UK market is witnessing increased investment in advanced POC technologies including digital integration, connectivity solutions, and AI-enabled diagnostic devices, positioning the country as a leader in next-generation point-of-care innovation.
UK Point of Care Diagnostics Market Dynamics
- Healthcare providers across England, Scotland, Wales, and Northern Ireland are prioritizing POC diagnostics to reduce diagnostic delays and improve clinical outcomes.
- The market will benefit from technological advancements, regulatory support, and integration with digital health platforms.
- Strategic partnerships between diagnostic manufacturers and UK healthcare systems are expected to accelerate market penetration.
- Additionally, post-pandemic emphasis on rapid response diagnostics and decentralized testing continues to fuel investment and adoption across all healthcare settings..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Stryker Corporation
- Abbott Laboratories
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- The UK Point of Care Diagnostics Market is valued at £257.9 million in 2024 and is projected to reach £434.7 million by 2029, representing a 68.6% increase over the forecast period.
- The UK market is growing at an 11.0% CAGR, significantly outpacing the global average of 8.5%, indicating strong regional demand and adoption momentum.
- NHS modernisation, primary care expansion, and digital health integration are primary growth drivers accelerating point-of-care diagnostic adoption across the UK.
- The UK market demonstrates particular strength in infectious disease testing, cardiac biomarkers, and glucose monitoring, with increasing deployment in community and urgent care settings.
Point of Care Diagnostics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | INFECTIOUS DISEASE TESTING PRODUCTS (Product) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 8.5% from 2024 to 2029 |
| Largest Segment | BLOOD SAMPLES (Sample) |
| Market Size Base Year (Billions) | ~USD 15.05 (2024) |
| Revenue Forecast (Billions) | ~USD 22.63 (2029) |
| Segments Covered | Product, Type, Sample, End User, Mode Of Purchase, Technology |
UK Point of Care Diagnostics Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product
- Cardiometabolic Monitoring Products
- Cholesterol Testing Products
- Coagulation Monitoring Products
- Drugs-Of-Abuse Testing Products
- Fecal Occult Testing Products
- Glucose Monitoring Products
- Hematology Testing Products
- Infectious Disease Testing Products
- Other Products
- Pregnancy & Fertility Testing Products
- Thyroid Stimulating Hormone Testing Products
- Tumor/Cancer Marker Testing Products
- Urinalysis Testing Products
By Type
- Act/Apit Testing Products
- Blood Gas/ Electrolyte Testing Products
- Cardiac Marker Testing Products
- Chlamydia Trachomatis Testing Products
- Clostridium Difficile Infection Testing Products
- Fertility Testing Products
- Glucose Monitoring Lancets & Lancing Devices
- Glucose Monitoring Meters
- Glucose Monitoring Strips
- Hba1C Testing Products
- Healthcare-Associated Infection Testing Products
- Hepatitis B Testing Products
- Hepatitis C Testing Products
- Hepatitis Testing Products
- Herpes Simplex Virus Testing Products
- Hiv Testing Products
- Human Papillomavirus Testing Products
- Inaat
- Influenza Testing Products
- Meters
- Neisseria Gonorrhea Testing Products
- Neisseria Gonorrhoea Testing Products
- Other Infectious Disease Testing Products
- Other Respiratory Infection Testing Products
- Pregnancy Testing Products
- Pt/Inr Testing Products
- Respiratory Infection Testing Products
- Rt-Pcr
- Sexually Transmitted Disease Testing Products
- Strips
- Syphilis Testing Products
- Tropical Disease Testing Products
- Tuberculosis
By Sample
- Blood Samples
- Nasal & Oropharyngeal Swabs
- Other Samples
- Urine Samples
By End User
- Ambulatory Care Facilities And Physician Offices
- Clinical Laboratories
- Home Care Settings And Self-Testing
- Hospitals, Critical Care Centers, And Urgent Care Centers
- Other End Users
By Mode Of Purchase
- Otc Testing Products
- Prescription-Based Testing Products
By Technology
- Biochemistry
- Immunoassays
- Molecular Diagnostics
Target Audience
- Diagnostic Device Manufacturers : Manufacturers need UK market data to develop localized product strategies, understand NHS procurement requirements, identify distribution partnerships, and capitalize on the 11% growth opportunity in this high-performing market.
- Healthcare Providers & NHS Trusts : UK hospitals, primary care networks, and diagnostic centers require market insights to benchmark their POC diagnostics capabilities, evaluate technology investments, and align procurement decisions with national health priorities.
- Private Equity & Investors : Investment firms and venture capitalists need comprehensive UK market analysis to identify acquisition targets, assess growth potential, evaluate exit opportunities, and make capital allocation decisions in the diagnostics sector.
- Healthcare Consultants & Advisors : Consulting firms supporting healthcare organizations need detailed UK market data to advise clients on diagnostic strategy, competitive positioning, technology adoption roadmaps, and operational efficiency improvements.
- Policy Makers & Health Authorities : UK government health departments and regulatory bodies require market intelligence to inform healthcare policy, allocate resources effectively, support NHS modernization initiatives, and drive evidence-based diagnostic service planning.
Key Companies in the UK Point of Care Diagnostics Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CEPHEID INC. | United States | Private Company | Infectious Disease POC (TB, HAI, STD, virology),Oncology and Genetics POC / near-patient MDx,Other POC (including emergency use, emerging pathogens such as Ebola), |
| UNILABS | Switzerland | Private Company | Glucose POC (primarily hospital and clinic-based),Infectious Disease POC (TB, HAI, STD),Pregnancy and Fertility-Linked POC, |
| EIKEN CHEMICAL CO., LTD. | Japan | Public Company | Glucose (POC),Infectious Disease POC (TB, HAI, STD and others),Pregnancy and other immunological POC tests, |
| ABBOTT | United States | Public Company | Glucose (POC and home monitoring within scope),Infectious Disease POC (including TB, HAI, STD, respiratory, HIV, others),Pregnancy and fertility POC, |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Glucose (Rx and OTC POC),Infectious Disease POC (TB, HAI, STD and others),Pregnancy and Fertility POC, |
| DANAHER | United States | Public Company | Glucose POC,Infectious Disease POC (incl. TB, HAI, STD),Pregnancy and Fertility POC, |
| QUIDELORTHO CORPORATION | United States | Public Company | POC Infectious Disease (incl. TB, HAI, STD, respiratory),POC Pregnancy and Fertility,POC Glucose and Metabolic, |
| BD | United States | Public Company | Glucose POC,Infectious Disease POC (TB, HAI, STD),Pregnancy and Other POC, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Glucose POC,Infectious Disease POC (TB, HAI, STD and others),Pregnancy and Fertility POC, |
| BIOMéRIEUX | France | Public Company | Infectious Disease POC (TB, HAI, STD, respiratory via BIOFIRE/SPOTFIRE, ARGENE near-patient use),Pregnancy and other immunoassay POC (VIDAS and related markers in near-patient settings),Glucose and basic biochemistry POC, |
| BIOSYNEX SA | France | Public Company | Glucose POC,Infectious Disease POC (TB, HAI, STD and others),Pregnancy and Fertility POC, |
| EKF DIAGNOSTICS HOLDINGS PLC | United Kingdom | Public Company | Glucose and Lactate Analyzers (Biosen, Lactate Scout, related),HbA1c and Hemoglobin POC Analyzers (Quo-Lab, Quo-Test, DiaSpect, Hemo Control, Hemo Vet),Pregnancy and Fertility (QuPID, True20, Creamatocrit Plus), |
| TRINITY BIOTECH | Ireland | Public Company | Glucose / Diabetes (incl. HbA1c-linked POC),Infectious Disease POC (TB, HAI, STD, viral),Pregnancy and Fertility POC, |
| BODITECH MED INC. | South Korea | Public Company | Glucose (POC),Infectious Disease (TB, HAI, STD, COVID-19 and others),Pregnancy and Fertility, |
CEPHEID INC.
CEPHEID INC. is a United States-based private company founded in 1996 with 1,700 employees specializing in molecular diagnostics.
UNILABS
UNILABS is a Swiss private company established in 1987 that operates clinical laboratory services with 1,897 employees.
EIKEN CHEMICAL CO., LTD.
EIKEN CHEMICAL CO., LTD. is a Japanese public company founded in 1939 with 696 employees engaged in chemical and diagnostic manufacturing.
ABBOTT
ABBOTT is a United States-based public company founded in 1888 with 115,000 employees operating in healthcare and diagnostics.
SIEMENS HEALTHINEERS AG
SIEMENS HEALTHINEERS AG is a German public company founded in 1896 with 72,369 employees providing medical technology and diagnostics solutions.
DANAHER
DANAHER is a United States-based public company founded in 1969 with 59,000 employees operating in diagnostics and life sciences.
QUIDELORTHO CORPORATION
QUIDELORTHO CORPORATION is a United States public company founded in 1979 with 6,500 employees specializing in diagnostic testing.
BD
BD is a United States-based public company founded in 1897 with 72,000 employees in medical technology and diagnostics.
THERMO FISHER SCIENTIFIC INC.
THERMO FISHER SCIENTIFIC INC. is a United States public company founded in 1956 with 125,000 employees providing life sciences and diagnostics solutions.
BIOMéRIEUX
BIOMéRIEUX is a French public company founded in 1963 with 14,894 employees specializing in in vitro diagnostics.
BIOSYNEX SA
BIOSYNEX SA is a French public company founded in 2005 with 397 employees in the diagnostic testing sector.
EKF DIAGNOSTICS HOLDINGS PLC
EKF DIAGNOSTICS HOLDINGS PLC is a United Kingdom public company founded in 1990 with 301 employees in clinical diagnostics.
TRINITY BIOTECH
TRINITY BIOTECH is an Irish public company founded in 1992 with 287 employees engaged in diagnostic product development.
BODITECH MED INC.
BODITECH MED INC. is a South Korean public company founded in 1998 with 541 employees in diagnostic device manufacturing.
Reasons to Buy this Report
- UK-Specific Market Intelligence : Gain detailed insights into the UK market dynamics, including NHS procurement trends, regional variations across England, Scotland, Wales, and Northern Ireland, and country-specific regulatory requirements affecting POC diagnostics adoption.
- Competitive Landscape Analysis : Understand the competitive positioning of major diagnostic manufacturers in the UK market, identify key players, assess market share distribution, and discover opportunities for differentiation in this high-growth segment.
- Growth Opportunity Identification : Leverage comprehensive data on the 11% CAGR to identify high-potential segments, emerging applications, and underserved clinical areas within UK healthcare where POC diagnostics adoption is accelerating fastest.
- Strategic Planning & Investment : Make informed decisions on market entry, expansion, or partnership strategies in the UK with validated forecasts, growth projections through 2029, and evidence-based insights into healthcare provider priorities and procurement patterns.
- Regulatory & Reimbursement Insights : Access UK-specific information on regulatory pathways, NICE guidance, NHS reimbursement models, and healthcare policy drivers that influence POC diagnostics adoption and market growth across different care settings.
Frequently asked questions
What is the current size of the UK Point of Care Diagnostics Market?
The UK Point of Care Diagnostics Market was valued at £257.9 million in 2024 and is expected to grow to £434.7 million by 2029.
What is the growth rate of the UK Point of Care Diagnostics Market?
The UK market is expanding at an 11.0% compound annual growth rate (CAGR) from 2024 to 2029, outperforming the global average of 8.5%.
Which diagnostic segments are driving growth in the UK market?
Infectious disease testing, cardiac biomarkers, and glucose monitoring are the primary segments driving growth in the UK Point of Care Diagnostics Market.
What factors are accelerating point-of-care adoption in the UK?
NHS modernisation initiatives, primary care expansion, digital health integration, and patient demand for convenient diagnostic solutions are key growth drivers in the UK.
How does the UK market compare to global trends?
The UK market is growing faster than the global average, with an 11.0% CAGR compared to the global 8.5% CAGR, reflecting strong regional healthcare investment and adoption.
RESEARCH METHODOLOGY
The study involved major activities to estimate the current market size of the Point of Care diagnostics market. Exhaustive secondary research was conducted to gather information on the market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the POC diagnostics market.
Secondary Research
This research study involved the extensive use of secondary sources, directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, white papers, and Companies House documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the POC diagnostics market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various supply- and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, VPs/Managing Directors, Marketing Heads/Directors, Sales Directors, Marketing/Sales Managers, Regional/Area Sales Managers, Export/Import Heads/Managers, and Other Market-Related Personnel from various companies and organizations operating in the POC diagnostics market. Primary sources from the demand side included Law Enforcement Agencies, Vice Presidents, C-level Executives, Department Heads, Enterprises, Individuals, Supply Management Teams of Hospitals, Clinic Personnel, and Laboratory Technicians.
Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Other primary roles include sales, marketing, and product management.
Note 3: Companies are classified into tiers based on their total revenue. As of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the POC diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The entire market was split into two segments when the market size was determined. Data triangulation and market breakdown were used as needed to complete the market engineering process and derive precise statistics for all segments.
Approach for deriving the market size and estimating market growth:
Using secondary data from paid and unpaid sources, the market rankings for the major players were determined through a thorough analysis of their POC diagnostic sales. Due to data restrictions, the revenue share in certain cases was determined after a thorough analysis of the product portfolio of big corporations and their individual sales performance. This information was verified at each stage by in-depth interviews with professionals in the field.
Market Definition
Point-of-care (POC) diagnostics refers to diagnostic testing performed at or near the patient's location, delivering rapid and accurate results to support immediate clinical decision-making. The market includes products such as blood glucose monitoring systems, infectious disease tests, cardiac biomarker assays, coagulation testing, blood gas and electrolyte analyzers, molecular diagnostics, pregnancy and fertility tests, urinalysis, and other rapid diagnostic solutions, serving hospitals, clinical laboratories, physician offices, ambulatory care facilities, retail clinics, pharmacies, and home healthcare settings.
Key Stakeholders
- Diagnostic device manufacturers
- Reagent and consumable suppliers
- Hospitals and clinical laboratories
- Physician offices and ambulatory care centers
- Pharmacies and home healthcare providers
- Medical device distributors
- Regulatory authorities
- Government and public health agencies
- Research organizations
- Healthcare IT providers
Report Objectives
- To describe, analyze, and forecast the POC diagnostics market, by product, sample, mode of purchase, technology, end user, and region
- To describe and forecast the POC diagnostics market for key regions, namely, North America, Europe, the Asia Pacific, Latin America and Middle East, and Africa
- To provide detailed information regarding drivers, restraints, opportunities, and challenges influencing the growth of the POC diagnostics market
- To strategically analyze the ecosystem, regulations, patenting trend, value chain, Porter’s five forces, and prices pertaining to the market under study
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players
- To profile key players and comprehensively analyze their market shares and core competencies2 in the POC diagnostics market
- To analyze competitive developments such as collaborations, acquisitions, product launches, expansions, and R&D activities in the POC diagnostics market
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of each company
Geographic Analysis
- Further breakdown of the Rest of Asia Pacific POC diagnostics market into Vietnam, New Zealand, and other markets.
- Further breakdown of the Rest of Latin America POC diagnostics market into Colombia, Chile, Ecuador, and others.
- Further breakdown of the Rest of Europe POC diagnostics market into Belgium, Russia, the Netherlands, Switzerland, and others.
Get the Full Point of Care Diagnostics Market Report
Full forecast, segment splits, and company analysis for all Point of Care Diagnostics Market.
- Canada Point of Care Diagnostics Market
- US Point of Care Diagnostics Market
- Germany Point of Care Diagnostics Market
- France Point of Care Diagnostics Market
- Italy Point of Care Diagnostics Market
- Spain Point of Care Diagnostics Market
- China Point of Care Diagnostics Market
- Japan Point of Care Diagnostics Market
- India Point of Care Diagnostics Market
- Australia Point of Care Diagnostics Market
- South Korea Point of Care Diagnostics Market
- Brazil Point of Care Diagnostics Market
- Mexico Point of Care Diagnostics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report